TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: blood Mn levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximal MAS Change From Baseline - Spasticity of Cerebral Origin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Maximal MAS Change From Baseline - Spasticity of Spinal Origin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Reduction of levothyroxine (LT4) mean dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of death and dying experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Staphylococcus aureus bloodstream infection
Endpoint domain: Adverse events/effects
Primary endpoint: Radiolucent lines on X-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about Down's syndrome screening
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Probability of response (confirmed complete and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite score for adherence to personal goals
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Bone mass (BMD, BMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neuropathy Impairment Score Lower Limb (NIS-LL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Quality of Life (TQOL) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Karnofsky Performance Scale (KPS) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Levels of inflammatory mediators in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of inflammatory mediators in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of inflammatory mediators in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Reporting Any Solicited Local Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Any Solicited General Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of colorectal cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ARV Hair Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cortical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: St George's Respiratory Questionnaire (SGRQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: modified Medical Research Council (mMRC) dyspnea scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hospital anxiety and depression score (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Expression of CD163 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of quantification of HCV viral load level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to successful blood sampling or IV catheter placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Induction of CEA specific T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response to oncofetal antigen 5T4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety, toxicity and tolerability of TroVax vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Experience of Botulinum toxin treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MRI Spectroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of RGO after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Coronary-artery calcium measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T1/2 (apparent terminal elimination half-life)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Pain Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient empowerment at 4, 6 and 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retention in care at one year
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Slow-wave sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Trail making test (TMT) A & B
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of i-scan OE system in predicting pathology types of colorectal polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clarity of images provided by the TrueVision system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High sensitivity cardiac troponin T (Hs-TnT) dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High Contrast Time Controlled Visual Acuity (TCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Required time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of recruiting
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of performing the procedure in recruited patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Offline consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Expression level of markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in office blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Segmental Assessment on Trunk Control-static
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Segmental Assessment on Trunk Control-active
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Segmental Assessment on Trunk Control-reactive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unintended Pregnancies
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence and severity of ocular and non-ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in deformational parameters in echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression of myocardial fibrosis and edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Tinetti Gait and Balance Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With All Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers (GMT) Specific for the Hemagglutinin (HA) Receptor Binding Domains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Rate (SCR) Specific for the HA Receptor Binding Domains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Follow-up outcomes of MAFLD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Hb >1 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of pre-cancer lesions or early cancer detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients who gained three or more lines of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Probability of First Virologic Failure by Week 96
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of Discontinuation of the RAL or PI Component of Randomized Treatment for Toxicity by Week 96
Endpoint domain: Adverse events/effects
Primary endpoint: Children's Knowledge of Abuse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge/Attitudes to Woman Abuse
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in Total Nasal Symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Geriatric Anxiety Inventory scores over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of labor success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with 18F-Florbetaben uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Platelet mRNA splicing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ticagrelor Pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rt-fMRI activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for BAY 84-3174
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for BAY 84-3174
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Motor Evoked Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of diverticular disease activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Evaluation of medical knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Evaluation of changes in professional practice
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Remission at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum plasma concentration of Ethinyl Estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum plasma concentration of Levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence and severity of GI adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Patient satisfaction change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of visual tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Speed for 10 Meter Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL and LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CPK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery measured by QoR-15
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intra-airway Positive inspiration pressure (PIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Modified Short Sensory Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusion-weighted imaging (DWI) lesion frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Patients Who Had a Minimal Residual Disease (MRD) Negative Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of post operational pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline fruit and vegetable knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline intention to consume fruit and vegetables
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Change from baseline attitude towards fruit and vegetable consumption
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in facial soft tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response after chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average trunk angle in the sagittal plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of LH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normal Neurodevelopment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Achieve Body Weight Reduction More Than or Equal to 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance in detecting breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Facial Dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain prevention/control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative Lees screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in % VP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquired methotrexate resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Completing at Least 80% of the Targeted Number of Sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete and Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory Abnormalities Defined as Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Eosinophilic Cationic Protein (ECP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in mean number of nocturnal voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inter-rater Reliability of Assessment of Facial Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intra-rater Reliability of Assessment of Facial Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in fractional contribution of DNL to total sebum palmitate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants attending health check
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Enrollment in social determinant of health resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urethrocystography realization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in renal blood flow during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Development of UTIs
Endpoint domain: Adverse events/effects
Primary endpoint: improvements in disease control rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Absence of thrombosis or stenosis of the popliteal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of prostate cancers detected by MP-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of clinically significant cancers detected by MP-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Burden Scale for Family Caregivers
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Geometric mean titer (GMT) for rabies plasma donations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of CIT-induction with Tremelimumab and Durvalumab
Endpoint domain: Adverse events/effects
Primary endpoint: adenosine polyphosphate level before treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mucin level before treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Experiencing Grade 3+ Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of NFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recurrence of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Burden of atrial fibrillation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in subjective sleep latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Relief of vaginal symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FDG uptake in the index vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing Diarrhea Caused by Clostridium Difficile
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ADAS Cog 11 Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in aneurysm wall inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Visual Analogue Scale (VAS) for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy using Hamilton Rating Scale for Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Treatment-emergent Serious Adverse Event (SAE) and Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Kaplan-Meier Estimate of the Probability of Discontinuation (d/c) From Study Drug
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants achieving remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Excursions <70 mg/dl Per Sensor Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of visilizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of SCH 727965
Endpoint domain: Adverse events/effects
Primary endpoint: Failure to achieve vaginal delivery
Endpoint domain: Mortality/survival
Primary endpoint: MACE complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Subjects Achieving Target Testosterone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of clinical composite events (death, stroke, coma, seizures, renal failure, AMI)
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive Biases Questionnaire for Psychosis
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Chronic breast pain using Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic breast pain using the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE 4.0)
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic breast pain using the prescription of pain killer
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Chronic breast pain using the McGill pain questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal endothelium cell number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion-specific Local Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse to heavy drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PCWP change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Pain in Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency room presentations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in DLCO SB alveolar volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes